Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.
about
Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathwaysTyrosine kinase signalling in breast cancer: fibroblast growth factors and their receptorsClinical and biological characteristics of cervical neoplasias with FGFR3 mutation.Aberrantly expressed microRNAs in the context of bladder tumorigenesisRecent developments in receptor tyrosine kinases targeted anticancer therapyMolecular Biomarkers in Bladder Cancer: Novel Potential Indicators of Prognosis and Treatment OutcomesMuscle-invasive urothelial bladder cancer: an update on systemic therapyTargeting RTK Signaling Pathways in CancerGenomic landscape of human papillomavirus-associated cancersGenomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumorsFunctional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancersA Molecular Brake in the Kinase Hinge Region Regulates the Activity of Receptor Tyrosine KinasesAntibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in miceStructural Mimicry of A-Loop Tyrosine Phosphorylation by a Pathogenic FGF Receptor 3 MutationSmall molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.Prognostic value of FGFR gene amplification in patients with different types of cancer: a systematic review and meta-analysis.Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutationsGenetic and Epigenetic Alterations in Bladder CancerInhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical applicationInvasive Bladder Cancer: Genomic Insights and Therapeutic PromiseSixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasiasInteraction of fibroblast growth factor receptor 3 and the adapter protein SH2-B. A role in STAT5 activationTargeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse modelsPatterns of somatic mutation in human cancer genomesA place for precision medicine in bladder cancer: targeting the FGFRs.Mutation-introduced dimerization of receptor tyrosine kinases: from protein structure aberrations to carcinogenesis.Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC)Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder.NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cellsFGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancerBiology of urothelial tumorigenesis: insights from genetically engineered mice.Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden.Frequency of activating mutations in FGFR2 exon 7 in bladder tumors from patients with early-onset and regular-onset disease.Controlling destiny through chemistry: small-molecule regulators of cell fate.Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumorsSomatic mutation of epidermal growth factor receptor in a small subset of cutaneous squamous cell carcinoma.Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration.Expression of fibroblast growth factor receptor 3 in the recurrence of non-muscle-invasive urothelial carcinoma of the bladder.Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells
P2860
Q24291107-E41F20E6-04E0-43AC-9B2B-53C8E90F1995Q24548250-792E7037-306E-4896-AFE1-1908B1A1A3FDQ24803000-78A6DE57-4CA3-4CA7-AC22-3A2FE9E7161CQ24805521-84023C0C-57A9-474F-A635-8302AEB8036CQ26744152-1C52F1C3-FC8F-4776-B278-B6A41123945DQ26751331-56A5B503-84F1-44F2-A467-AD971C9264BCQ26765922-BE80E3E6-FC09-4876-A6A0-0236DCDCBA38Q26775780-A4735972-22B0-42D3-8BEC-FC3E918AE1B4Q26781278-B31E4F5F-4E51-4182-AC57-DBCF877B60E4Q26997399-54074A75-FF14-469D-A3EB-3696A2110B49Q26998790-FE48E06C-12E1-47C2-9407-10AE1A00AE54Q26998955-3AC4F9F1-A262-4C52-A41B-831C13EB98E4Q27647832-9B494169-CEEA-498C-A648-563A6049042FQ27654979-F3BB28EE-9F4C-4ECD-8220-42675D37C753Q27679792-7F9C6D5B-5CC7-4FD1-9C1F-D3552F81C0B4Q27851612-7F26B68E-4817-4D5C-AA25-EE55CFD854FBQ27853061-7674246E-A1CA-47AC-AEEF-72CB9CB4834CQ27853244-DD300820-ABC4-4885-A1C0-C3DDF07E92BDQ28074732-B5F85AA6-62CC-4636-8BFD-12E837A1A309Q28079309-9B2881E2-EC32-48DD-9563-2306DC26AC60Q28088334-A3D8EF8C-8356-4646-9907-835408C05D54Q28252023-4853D84B-692F-4406-B82B-94DBDFF7D3C9Q28592322-38D378E8-32B9-415D-84E9-D8876F80D8E7Q28729944-9443E333-FCCD-4315-9744-43BCA1C705C9Q29547841-368EF35C-90C7-4060-8025-CFC64712653BQ30249143-2D2FA7C3-22C7-4BCC-B263-887548E6BD39Q30372506-137BC29A-939B-4230-B872-1C66E55CD401Q30433431-D1C4F9AA-C7DF-49FF-8F8C-0626FD76E4FFQ30857433-7C2A8833-3B76-4F1A-A4DC-344D1D93CFF9Q30982341-AB3FC1DF-EE18-4705-A5A3-D0711FE7B59FQ33292711-904699C9-5060-46CC-9194-EDEC116D5C21Q33554361-FC72C202-16D3-40BD-8A67-DCBA39436751Q33568623-6801C056-CA89-4EAD-B238-DCCFA6190DFAQ33583057-05BC3423-BEA3-4CF1-9F35-F80DF771D8C1Q33593482-80E28427-D106-4CE6-B4F4-FFE8FEE8F4B8Q33633815-2C08EFF9-8748-4B72-BBE5-92EABFCC68AEQ33671646-C85078B7-53EC-429F-84A4-9DFD1E0361DCQ33783047-ABD157B0-0A79-4A6E-8E20-918F717C0F3AQ33792915-54A3C48F-BFBD-42D7-B62F-34F0E127E790Q33860674-37F7020A-9A1B-4B6C-BF98-E3E54FB8715F
P2860
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.
@en
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.
@nl
type
label
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.
@en
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.
@nl
prefLabel
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.
@en
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.
@nl
P2093
P356
P1433
P1476
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
@en
P2093
Cappellen D
De Oliveira C
de Medina S
P2888
P356
10.1038/12615
P407
P577
1999-09-01T00:00:00Z
P6179
1033667774